B62-14 Frequency of Guideline-based ICS-containing Reliever Therapy Prescribing After Pediatric Asthma ED Encounters in an Urban Academic Medical Center
Abstract
In 2019, the Global Initiative for Asthma (GINA) introduced a major update to asthma management which recommend the use of inhaled corticosteroids (ICS), rather than short-acting beta-agonists (SABA) alone, as a key component of asthma reliever therapy for individuals of all ages, regardless of asthma severity. Despite the recent shift in global asthma management, prescription rates of ICS-containing reliever therapy (e.g., ICS/SABA or ICS/LABA) following an asthma-related emergency department (ED) visit in adult EDs remain low, yet no studies to date have explored this important issue within pediatric EDs. We aimed to assess the frequency with which pediatric patients receive ICS-containing reliever therapy prescriptions following an asthma-related ED visit in a Chicago-area pediatric ED.
We conducted a retrospective analysis of ICS-containing reliever and SABA prescriptions issued after asthma-related encounters in a pediatric emergency department at a Chicago academic medical center among patients ≤17 years of age, from January 1, 2020 through January 1, 2025 (i.e., following the 2019 GINA update). Synthetic data was used through the MDClone ADAMS Platform and included additional demographic data such as patient age, sex, race/ethnicity, and insurance type. Only encounters resulting in ED discharge were analyzed. Descriptive statistics were used for analysis.
Between 2020-2025, 6245 emergency department asthma encounters were identified. Patients had a median age of 7.6…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.